Adnan Khan, H. M. Ross, N. Parra, Sarah L. Chen, Kashyap Chauhan, Makala Wang, Binghai Yan, John Magagna, Jake Beiriger, Y. Shah, Taha Shahzad, D. Halegoua-DeMarzio
{"title":"Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD)","authors":"Adnan Khan, H. M. Ross, N. Parra, Sarah L. Chen, Kashyap Chauhan, Makala Wang, Binghai Yan, John Magagna, Jake Beiriger, Y. Shah, Taha Shahzad, D. Halegoua-DeMarzio","doi":"10.3390/livers2040022","DOIUrl":null,"url":null,"abstract":"Non-alcoholic fatty liver disease (NAFLD) is a serious clinicopathological condition that is recognized as the most frequent chronic liver disease, affecting 14%-30% of the world’s population. The prevalence of NAFLD has rapidly grown and is correlated with the growth in obesity and type 2 diabetes, among other factors. NAFLD often results in long-term complications including cardiovascular disease, liver cirrhosis, and liver fibrosis. This paper provides an updated overview of NAFLD with a focus on epidemiology, etiology, pathophysiology, screening, complications, and pharmacological therapies to identify effective risk prevention and health promotion.","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Livers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/livers2040022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a serious clinicopathological condition that is recognized as the most frequent chronic liver disease, affecting 14%-30% of the world’s population. The prevalence of NAFLD has rapidly grown and is correlated with the growth in obesity and type 2 diabetes, among other factors. NAFLD often results in long-term complications including cardiovascular disease, liver cirrhosis, and liver fibrosis. This paper provides an updated overview of NAFLD with a focus on epidemiology, etiology, pathophysiology, screening, complications, and pharmacological therapies to identify effective risk prevention and health promotion.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
